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Abstract
Background: Previous cohort studies have demonstrated the beneficial effects of antiretroviral therapy (ART) on
viral load suppression. We aimed to examine the factors associated with virologic suppression for HIV-infected
patients on ART receiving care at the Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation in Rio
de Janeiro, Brazil.
Methods: HIV-1 RNA levels and CD4+ T-cell counts at the date closest to midyear (1 July) were evaluated for 1,678
ART-naïve patients ≥18 years of age initiating ART between 1997 and 2010. The odds ratios (OR) and 95%
confidence intervals (CI) for having an undetectable viral load (≤400 copies/mL) were estimated using generalized
estimating equations regression models adjusted for clinical and demographic factors. Time-updated covariates
included age, years since HIV diagnosis, hepatitis C diagnosis and ART interruptions.
Results: Between 1997 and 2011, the proportion of patients with an undetectable viral load increased from 6% to
78% and the median [interquartile range] CD4+ T-cell count increased from 207 [162, 343] to 554 [382, 743] cells/μL.
Pre-treatment median CD4+ T-cell count significantly increased over the observation period from 114 [37, 161] to 237
[76, 333] cells/μL (p < .001). The per-year adjusted OR (aOR) for having undetectable viral load was 1.18 (95% CI =
1.16-1.21). ART interruptions >1 month per calendar significantly decreased the odds [aOR = 0.32 (95% CI = 0.27-
0.38)] of having an undetectable viral load. Patients initiating on a protease inhibitor (PI)-based first-line regimen
were less likely to have undetectable viral load [aOR = 0.72 (95% CI = 0.63-0.83)] compared to those initiating on a
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen.
Conclusions: Our results demonstrate significant improvements in virologic outcomes from 1997 to 2011, which
persisted after adjusting for other factors. This may in part be due to improvements in care and new treatment
options. NNRTI- versus PI-based first-line regimens were found to be associated with increased odds of having an
undetectable viral load, consistent with previous studies. Treatment interruptions were found to be the most
important determinant of not having an undetectable viral load. Studies are needed to characterize the reasons
for treatment interruptions and to develop subsequent strategies for improving adherence to ART.
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Background
Universal access to antiretroviral therapy (ART) for
human immunodeficiency virus (HIV) infection was
first established in Brazil by a federal decree issued in
1996. Over time, the Ministry of Health has continued
efforts to expand HIV testing and treatment programs.
CD4+ T-cell count thresholds for treatment initiation
have increased over time and newer first-, second- and
salvage-line antiretroviral drugs with greater efficacy
and lower toxicity profiles have been introduced within
the National AIDS Program. The early introduction of
viral load monitoring within the National ART guide-
lines in Brazil has also allowed for earlier detection of
virologic failure and subsequent treatment modifica-
tions. Data from previous studies conducted in both
high- and low-resource settings have validated the im-
pact of ART on decreasing morbidity and mortality,
and achieving virologic suppression and immune system
reconstitution for HIV-infected persons [1-10].
Given the importance of maintaining virologic suppres-
sion for reducing the risk of clinical progression of HIV
and ultimately death, as well as decreasing HIV transmis-
sibility [11], studies have analyzed the association between
clinical and demographic factors and HIV-1 RNA levels to
determine factors associated with virologic suppression
[5,9]. Data from the Swiss HIV Cohort found treatment
interruptions and poor adherence to be the most pre-
dictive factors of not maintaining virologic suppression
[5]. In Brazil, there are published data regarding predic-
tors of virologic response after ART initiation; however,
there are limited data regarding population-level long-
term response to ART [6].
This analysis aimed to examine the virologic and im-
munologic response to HIV treatment, including factors
associated with virologic suppression for HIV-infected
patients on ART receiving care at the Evandro Chagas
Clinical Research Institute (IPEC) of the Oswaldo Cruz
Foundation (Fiocruz) in Rio de Janeiro, Brazil from
1997 to 2011. Our analysis, though not representative
of the overall Brazilian HIV-infected population, re-
flects the group-level effects of provision of universal
access to ART and continued efforts to improve care




Data were obtained from the longitudinal, clinical data-
base of HIV-infected patients receiving care at IPEC in
Rio de Janeiro, Brazil. IPEC has been providing care to
HIV-infected patients since 1986. The clinical database
was established in 1998 and has since been updated
regularly using outpatient and inpatient medical records,
and laboratory results. ART regimen data, including
drug type, dose and prescription dates, is documented
by the medical provider in the medical record. Profes-
sional abstractors review all patient records on a continu-
ous basis and record the information onto standardized
forms, which are subsequently scanned for inclusion in
the clinical database.
We analyzed data for HIV-infected patients greater
than or equal to 18 years of age who initiated highly-
active ART for the first time during the period from
January 1, 1997 through December 31, 2010. Patients
initiating ART prior to enrollment in the IPEC clinical
cohort were excluded from the analysis. Only patients
initiating ART on a non-nucleoside reverse transcriptase
inhibitor- (NNRTI) or protease inhibitor- (PI) based regi-
men were included. NNRTI-based regimens were defined
as a NNRTI or NNRTI and PI, plus nucleoside reverse
transcriptase inhibitor (NRTI) backbone. PI-based regi-
mens were defined as a PI plus NRTI backbone only. Pa-
tients initiating on neither NNRTI- or PI-based first-line
regimens were too few (n = 28) to include in our statistical
analysis and were therefore excluded. End of follow-up
was determined by either year of death for patients with a
documented date of death or until the last year of the
period of analysis, December 31, 2011.
Variables of interest
HIV-1 RNA levels and CD4+ T-cell counts at the date
closest to midyear (1 July) were evaluated for all patients
initiating ART between 1997 and 2011. Only HIV-1
RNA levels and CD4+ T-cell counts occurring greater
than or equal to 90 days after the initiation of ART were
included in the analysis to allow time for virologic re-
sponse to treatment. The outcome of interest was un-
detectable viral load, defined as ≤400 copies/mL to
account for less sensitive virus detection thresholds of
older testing platforms included in the analysis.
Antiretroviral regimens were classified by drug mechan-
ism of action. No distinction was made for drug genera-
tions or agents within the same drug class. Individual ART
regimens per calendar year were determined by choosing
the regimen with the greatest number of documented
months per calendar year. Treatment interruptions per
calendar year were defined as the sum of all the periods of
time with no documented ART regimen in the patient’s
clinical chart, rounded to the nearest month, and not
necessarily occurring consecutively.
Demographic characteristics were also assessed, which
included: age, gender, race, years of formal schooling,
self-reported risk group and date of HIV diagnosis. Race
was categorized as White and Non-White. HIV risk group
was hierarchically categorized as Injection Drug Users
(IDU), Men who Have Sex with Men (MSM), Heterosexual
Men, Heterosexual Women, and Other. The “Other”
risk group category includes hemophiliacs, occupational
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exposures, and transfusions. Covariates of interest included
pre-treatment CD4+ T-cell count, defined as CD4+ T-cell
count occurring within 180 days prior to ART initiation,
and lifetime occurrence of hepatitis C diagnosis, defined
as the presence of hepatitis C antibodies. Pre-treatment
CD4+ T-cell counts were categorized as follows: ≤200,
201–350, 351–500, >500 and missing. Pre-treatment viral
load data were not universally available.
Statistical methods
HIV-1 RNA levels were stratified as ≤400, 401–1,000,
1,001-100,000 and ≥100,001 copies/mL. Median and inter-
quartile ranges (IQR) of CD4+ T-cell counts were com-
puted for each calendar year. Time trends for categorical
and continuous variables were tested using the Chi-square
and Kruskal-Wallis test respectively, assuming a signifi-
cance level of p < 0.05.
Unadjusted and adjusted logistic regression models were
used to describe the association of clinical and demo-
graphic factors with the odds of having an undetectable
viral load. Generalized estimating equations (GEE) were
used to account for repeated measures per patient. Time
trends were analyzed by using calendar year as a continu-
ous variable. The following fixed covariates were included
in the model: sex, race, education level, risk group, pre-
treatment CD4+ T-cell count and initial ART regimen.
Missing values for race and education categories for 5 and
8 patients, respectively, were imputed based on sample
distribution. Time-updated covariates included age in
years (strata: <30, 30–39, 40–49 and ≥50), years since HIV
diagnosis, ART interruptions (categorized as ≤1 month
versus >1 month), and hepatitis C diagnosis (history of
positive anti-HCV antibody test). ART interruptions were
categorized because the variable was not linearly associ-
ated with the outcome when treated as a continuous vari-
able (data not shown). Given that the duration of ART
interruption did not necessarily represent a continuous
interval of time, the variable was categorized as interrup-
tions ≤1 month versus >1 month per calendar year. ART
regimen was not included as a time-updated covariate due
to limitations in the formatting of the longitudinal dataset.
Patients with missing mid-year viral load outcomes were
excluded from the logistic regression analysis for the years
where they had no viral load outcomes. A sensitivity
analysis assuming that all missing virologic outcomes
were detectable was performed. Analyses were done
using R-software (version 2.15.1).
Ethical approval
This study was approved by the institutional review
board of IPEC. Written informed consent for enrollment
in the cohort was obtained from all patients. Retrospect-
ive analysis of previously collected data delinked from
personal identifying information was considered exempt
by the UCLA IRB.
Results
Demographic and clinical time trends
A total of 1,678 patients initiated ART from 1997 to 2010
and contributed at least one viral load outcome to the
descriptive and logistic regression analysis. There were
a total of 8,870 years of follow-up included in the obser-
vation period. The median [IQR] number of months of
follow-up per patient was 47 [29, 79] months.
Table 1 shows the demographic and clinical characteris-
tics for new patients initiating ART over time. A compari-
son of the demographic characteristics of new patients
included per year showed a significant increase in non-
white (p < 0.001) and older patients (p < 0.05), as well as
heterosexual men entering the cohort each calendar year
(p < 0.001).
Figure 1 depicts pre-treatment CD4+ T-cell counts
and the primary ART regimens in use per calendar year.
Pre-treatment median CD4+ T-cell count significantly
increased over the observation period from 114 [37, 161]
to 237 [76, 333] cells/μL (p < 0.001). A total of 248 patients
did not have a documented pre-treatment CD4+ T-cell
count, of which 114 (46%) had a documented acquired
immunodeficiency syndrome- (AIDS) defining illness in
their clinical chart within the period 90-days prior to
30-days post initiation of ART.
The ratio of patients on NNRTI- versus PI-based regi-
men increased over time, most notably after the year
2000. The number of patients on non-NNRTI- or non-PI-
based regimens (depicted as “Other Regimen” in Figure 1)
remained stable over time, representing approximately less
than 10% of the overall cohort population. The percent of
patients with no documented ART regimen in the clinical
chart for an entire calendar year (depicted as “No Regimen
Documented” Figure 1) varied from 3 to 9% of all patients
per year. However, the proportion of patients with an
ART interruption of greater than one month duration
decreased from 64% in 1997 to 16% in 2011.
Out of the 8,770 years of follow-up, there were a total
of 2,245 ART interruptions of more than one month
duration. The median number of total months of treat-
ment interruption per calendar year was 7 [4, 12]. The
proportion of patients with a treatment interruption of
more than one month duration trended downward from
64% in 1997 to 16% in 2011. Overall, 74% of patients
(1,240/1,678) had at least one year with an ART inter-
ruption of more than one month duration, with a me-
dian of 2 [1, 5] years with an interruption per patient.
The median number of months of follow-up per patient
for these patients was 51 [29, 88] compared to 47 [26,
71] months for those who never had an ART interrup-
tion of more than one month duration. Demographic
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characteristics of the patients who never had an ART
interruption were overall similar to those who had at
least one ART interruption with the exception of there
being a greater percentage of IDU in the latter group.
The median number of viral load measurements per
patient per year was 1 [0.8, 1]. Patients contributed a
total of 7,278 viral load outcomes. The percentage of pa-
tients with a missing viral load outcome decreased from
44% in 1997 to 13% in 2011. Of note, over 78% of patients
with a missing viral load outcome had a greater than one
month ART interruption documented during the corre-
sponding calendar year.
During the observation period, the overall proportion
of patients with an undetectable viral load increased
from 6% in 1997 to 78% in 2011. Additionally, the me-
dian CD4+ T-cell count increased from 207 [162, 343]
to 554 [382, 743] cells/μL. The proportion of midyear
HIV-1 RNA levels stratified by number of viral copies
and median midyear CD4+ T-cell counts per calendar
year are depicted in Figure 2.
Factors associated with undetectable viral load
Table 2 displays the results of the unadjusted and adjusted
GEE logistic regression models for having an undetectable
viral load. The per-year unadjusted odds ratio (OR) was
1.20 (95% CI =1.17-1.22). After adjusting for clinical and
demographic factors, time trends remained significant,
with a per-year adjusted OR of 1.18 (95% CI = 1.16-1.21).
The following variables within the Risk Group and Pre-
Treatment CD4+ categories had significant negative as-
sociations with the outcome only in the unadjusted
model respectively: Heterosexual Woman, IDU, and
Other; and >500 cells/μL and Missing.
Older age and more years of formal schooling were
positively associated with having an undetectable viral
load. ART interruptions >1 month versus ≤1 month per
calendar year and initiating a PI-based first-line regimen
compared to an NNRTI-based first-line regimen were
the factors most strongly negatively associated with hav-
ing an undetectable viral load. The odds of having an
undetectable viral load decreased with each year since
Table 1 Demographic and clinical characteristics of new patients over time, Rio de Janeiro, Brazil, 1998-2010*
1998 2000 2002 2004 2006 2008 2010 Overall P-value
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
New patients 30 - 79 - 80 - 75 - 136 - 286 - 241 - 1678 -
Gender
Male 19 (63) 48 (61) 53 (66) 51 (68) 103 (76) 203 (71) 173 (72) 1163 (69) 0.21
Female 11 (37) 31 (39) 27 (34) 24 (32) 33 (24) 83 (29) 68 (28) 515 (31)
Race
White 16 (53) 53 (67) 53 (66) 41 (55) 80 (59) 140 (49) 101 (42) 882 (53) < 0.001
Non-white 14 (47) 26 (33) 27 (34) 34 (45) 56 (41) 146 (51) 140 (58) 796 (47)
Age (years)
<30 5 (17) 25 (32) 20 (25) 14 (19) 21 (15) 69 (24) 65 (27) 370 (22) <0.01
30-39 12 (40) 29 (37) 31 (39) 24 (32) 62 (46) 107 (37) 87 (36) 635 (38)
40-49 11 (37) 17 (22) 19 (24) 28 (37) 32 (24) 76 (27) 63 (26) 468 (28)
>50 2 (7) 8 (10) 10 (13) 9 (12) 21 (15) 34 (12) 26 (11) 205 (12)
Risk group
HT man 4 (13) 13 (16) 25 (31) 21 (28) 38 (28) 75 (26) 56 (23) 429 (26) < 0.001
HT woman 7 (23) 23 (29) 20 (25) 18 (24) 24 (18) 72 (25) 55 (23) 410 (24)
MSM 10 (33) 31 (39) 21 (26) 21 (28) 48 (35) 103 (36) 87 (36) 554 (33)
IDU 4 (13) 1 (1) 0 (0) 1 (1) 0 (0) 3 (1) 2 (1) 19 (1)
Unknown 2 (7) 11 (14) 13 (16) 13 (17) 25 (18) 31 (11) 40 (17) 249 (15)
Other 3 (10) 0 (0) 1 (1) 1 (1) 1 (1) 2 (1) 1 (0) 17 (1)
Education (years)
≤ 8 years 16 (53) 44 (56) 50 (63) 42 (56) 69 (51) 149 (52) 120 (50) 886 (53) 0.40
> 8 years 14 (47) 35 (44) 30 (38) 33 (44) 67 (49) 137 (48) 121 (50) 792 (47)
Hep C coinfection 3 (10) 4 (5) 4 (5) 6 (8) 8 (6) 15 (5) 9 (4) 83 (5) 0.46
*Odd years not shown. Bold text indicates p-value < 0.05. HT, heterosexual; MSM, men who have sex with men; IDU, injecting drug user; Hep, hepatitis.
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HIV diagnosis. Patients with a pre-treatment CD4+ T-
cell count between 351 and 500 cells/μL had an in-
creased odds of being undetectable compared to those
initiating with a CD4+ T-cell count ≤200 cells/μL.
Sensitivity analysis
A total of 1,492 missing mid-year viral load outcomes
(1,492/8,770; 17%) were excluded from the analysis. Sen-
sitivity analysis assuming all missing mid-year viral load
outcomes as detectable did attenuate the overall effect
(per-year adjusted OR = 1.14, 95% CI = 1.12-1.16), but
did not offset overall time trends or significantly affect
the factors associated with undetectable viral load.
Discussion
In our observational, clinical cohort, significant improve-
ments in virologic outcomes were observed for patients
receiving ART over the study period. Between 1997 and
2011, the proportion of patients with an undetectable
viral load increased from 7% to 78% and the median
CD4+ cell count increased from 207 [162, 343] to 554
[382, 743] cells/μL. Time trends in virologic outcomes
Figure 1 Trends in (a) pre-treatment CD4 and (b) ART regimen profile per calendar year. Numbers in columns represent the number of
patients prescribed the ART regimen.
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were only partially explained by the clinical and demo-
graphic factors tested, thus other factors not accounted
for in our model, such as improvements in clinical care,
treatment options and ART adherence may explain our
findings. Our results are consistent with prior studies
which suggest that these observed trends in virologic
and immunologic outcomes may be partly attributable
to improvements in treatment and care [4-10], such as
increasing clinician experience [12], improvements in
dosing and efficacy of ART regimens, and improved pa-
tient knowledge and adherence [1]. In particular, the
introduction of newer drugs and drug classes in Brazil,
such as raltegravir, darunavir, etravirine and enfuvirtide,
within the ART guidelines for salvage therapy, as well as
use of resistance testing to guide regimen changes after
treatment failure have undoubtedly played a role in the
observed improvements over time.
Similar to a prior study of predictors of virologic sup-
pression [5], we found treatment interruptions to be the
strongest negatively correlated predictor of having an
undetectable viral load. Of note, there was a consider-
able decrease in the proportion of patients with an ART
interruption of greater than one month duration per cal-
endar year. This observed decrease in ART interruptions
Figure 2 Trends over time in (a) midyear viral load categories and (b) median midyear CD4+ T-cell counts per calendar year for
1,678 individuals.
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may be a consequence of improved adherence due to in-
creased patient knowledge and better drug tolerance
profiles.
Even though treatment interruptions were assumed
from absence of documentation of ART regimen within
the patient clinical record and not confirmed with the
ARV pharmacy database, it is unlikely that patients with
no documented regimen were still retrieving their medi-
cations because a physician prescription is required for
medication dispensation. Lack of treatment documenta-
tion in the clinical chart is therefore likely a surrogate for
periods of medication non-adherence or loss-to-follow-up.
We did not apply a definition of loss-to-follow-up for
excluding patients from the analysis, thus all patients
ever initiated on treatment were accounted for until the
end of the observation period or documented date of
death. The rationale for this was that vital status is ex-
haustively verified through active patient contact and
Table 2 Factors associated with undetectable HIV-RNA level (≤400 copies/mL), Rio de Janeiro, Brazil, 1997-2011
Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Year 1.2 (1.17 - 1.22) <0.001 1.18 (1.16 - 1.21) <0.001
Ethnicity
White 1.00 (reference) 1.00 (reference)
Non-white 0.98 (0.86 - 1.1) 0.70 0.97 (0.84 - 1.11) 0.62
Risk group
Heterosexual man 1.00 (reference) 1.00 (reference)
Heterosexual woman 0.83 (0.7 - 0.98) 0.03 0.93 (0.78 - 1.12) 0.46
MSM 1.02 (0.86 - 1.2) 0.85 1.05 (0.87 - 1.27) 0.61
IDU 0.48 (0.31 - 0.75) <0.01 0.88 (0.5 - 1.56) 0.66
Unknown 0.99 (0.8 - 1.27) 0.91 1.08 (0.86 - 1.37) 0.50
Other 0.46 (0.28 - 0.75) <0.001 0.78 (0.46 - 1.3) 0.34
Education (years)
≤8 1.00 (reference) 1.00 (reference)
>8 1.66 (1.46 - 1.88) <0.001 1.69 (1.47 - 1.95) <0.001
Age* (years)
<30 1,00 (reference) 1.00 (reference)
30-39 1.14 (0.94 - 1.37) 0.19 1.22 (0.98 - 1.5) 0.07
40-49 1.55 (1.27 - 1.88) <0.001 1.68 (1.34 - 2.11) <0.001
≥50 1.98 (1.57 - 2.49) <0.001 2.11 (1.61 - 2.77) <0.001
Years since HIV diagnosis* 0.98 (0.97 - 1) 0.01 0.92 (0.91 - 0.94) <0.001
Pre-treatment CD4+
≤200 1.00 (reference) 1.00 (reference)
201-350 1.01 (0.87 - 1.18) 0.87 0.97 (0.82 - 1.14) 0.73
351-500 1.19 (0.95 - 1.5) 0.12 1.3 (1.02 - 1.64) 0.03
>500 0.64 (0.49 - 0.83) <0.001 0.93 (0.7 - 1.24) 0.62
Missing 0.75 (0.62 - 0.89) <0.001 0.84 (0.69 - 1.02) 0.08
Initial regimen
NRTI + NNRTI 1.00 (reference) 1.00 (reference)
NRTI + PI 0.56 (0.5 - 0.64) <0.001 0.72 (0.63 - 0.83) <0.001
ART interruption*
≤1 month 1.00 (reference) 1.00 (reference)
>1 month 0.29 (0.25 - 0.37) <0.001 0.32 (0.27 - 0.38) <0.001
Hep C coinfection* 1.01 (0.8 - 1.27) 0.95 1.09 (0.84 - 1.42) 0.50
Results from unadjusted and adjusted logistic regression generalized estimating equations models. A total of 1,492 missing midyear viral load outcomes were
excluded from the analysis. OR, odds ratio; CI, confidence interval; MSM, men who have sex with men; IDU, injecting drug user; NRTI, nucleoside reverse
transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Hep, Hepatitis. *Time-updated variables. Bold text indicates
p-value < 0.05.
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data linkage with state-wide mortality databases using a
previously validated algorithm [13], thus it is unlikely
that patients with missing information have died. Given
that a large percentage of the patients who did not have
an available viral load result also had a treatment inter-
ruption during the corresponding calendar year, it may
well be that some of these patients were temporarily
disconnected from care.
The number of months of follow-up per patient was
only slightly higher in the group of patients with at least
one versus no ART interruption throughout the study
period, thus having no ART interruption is not merely an
artifact of differences in follow-up time between the two
groups. Given the importance of ART adherence to treat-
ment efficacy [1], development of ART resistance [14],
and mortality reduction [15], future research is needed to
characterize the reasons for treatment interruptions [16].
We also found older age (≥40 years) [17] and more
years of schooling to be associated with increased odds
of having an undetectable viral load. This may be attrib-
utable to increasing levels of medication non-adherence
among younger and less educated patients. Both younger
age [18,19] and fewer years of education [18] have been
shown to be independently associated with measures of
non-adherence. Patients with lower levels of education
may have increased difficulty understanding the infor-
mation provided by the healthcare team, which may
negatively impact patient adherence to treatment [20].
Our study was limited by the open cohort design,
which is subject to bias both from the inclusion of new
patients who may have improved prognoses, as well as
the loss of patients with potentially poorer prognoses.
We did not conduct a closed cohort analysis, however, a
prior study found no difference in time trends for viro-
logic outcomes when comparing a closed versus open
cohort [5]. Our results did demonstrate a significant in-
crease in pre-treatment CD4+ T-cell counts per calen-
dar year for patients starting ART, which may partially
account for the improving time trends in virologic and
immunologic response to ART [21-24]. Our results also
reflect the increase in CD4+ T-cell count ART initiation
threshold to 350 cells/μL by the Brazilian National AIDS
Program in 2006, but also demonstrate that a majority of
patients still initiate treatment below the recommended
threshold (given that the median pre-treatment CD4+
T-cell count in 2010 was 237) [76, 333]. That is not sur-
prising given that the majority of patients newly pre-
senting for HIV care at our site continue to present with
a CD4+ T-cell count <350 cells/μL [25].
Another study limitation was the inability to account
for possible viral load blips in our analysis due to the
limited quantity of viral load tests performed per patient
per year. Despite the fact that Brazilian HIV treatment
guidelines stipulate routine viral load and CD4+ T-cell
count testing every three to four months for patients on
ART, most patients received viral load testing only once
per year (median of 1 [0.8, 1] viral load measurement
per patient per year).
Of note, patients with a pre-treatment CD4+ T-cell
count between 351 and 500 cells/μL were found to have
increased odds of having an undetectable viral load in the
adjusted model. Having no documented pre-treatment
CD4+ T-cell count was negatively associated with our out-
come in the unadjusted model. This trend persisted in the
adjusted model but achieved only borderline significance
(p < 0.10). Patients with missing pre-treatment CD4+ T-
cell counts likely initiated treatment based on clinical
criteria, and thus were likely to be severely immunosup-
pressed at the time of treatment initiation. Of the pa-
tients with missing pre-treatment CD4+ T-cell counts,
46% had a documented AIDS-defining clinical condi-
tion 90-days prior to or 30-days post initiating ART
compared to 32% of those with a pre-treatment CD4+
T-cell count.
We were unable to account for the impact of ART regi-
men changes (both inter- and intra-class drug changes)
within our logistical regression model. However, we did
find that initiating a PI- versus NNRTI-based first-line
regimen was negatively correlated with the likelihood of
having an undetectable viral load, consistent with prior
research which showed virologic failure was less likely
in patients initiating treatment with regimens contain-
ing efavirenz versus lopinavir-ritonavir [26]. Of note,
lopinavir-ritonavir is the most frequently used PI in our
patient population, in accordance with National ART
guidelines.
We addressed the possible effects of selection bias due
to exclusion of patients with missing viral load outcomes
by modeling a worst-case scenario that categorized all
missing virologic outcomes as detectable (>400 copies/mL)
viral loads. Treating missing outcomes as failures did
attenuate the magnitude of the effect, but did not change
the overall time trends.
Conclusions
In conclusion, we found significant improvements in vi-
rologic outcomes in a large, urban, publicly run Brazilian
clinic from 1997 to 2011 that persisted after adjusting
for other factors. This suggests that other unmeasured
variables, such as advances in ART dosing and efficacy,
for which time is a surrogate, may be contributing to
the improvement in HIV-1 viral load suppression. Even
though we cannot ensure our results are representative
of the entire population of HIV/AIDS patients receiving
care nationwide, they are very likely to represent those
receiving care in large urban centers in Brazil. More-
over, the increase in the proportion of patients on ART
with undetectable viral load levels within our clinical
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cohort may have implications for the overall community-
level reduction of HIV transmission, and should encour-
age the continued expansion of HIV testing and treatment
programs in Brazil.
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